Abstract: Intraocular metastases almost invariably arise in the uveal tract, mostly in the posterior choroid. They are the most common type of intraocular malignancy and often the first sign of tumor dissemination. Choroidal metastases generally appear as a creamy white or pale yellow mass associated with subretinal fluid and may be multifocal and bilateral. The most common primary sites are the breast and lung. Diagnosis is aided by a variety of tests, particularly ultrasonography and optical coherence tomography. Intraocular biopsy is useful in patients with clinical suspicion of uveal metastasis but no evidence of primary malignancy despite systemic evaluation. If systemic treatment fails to control the ocular tumor, a good response is usually achieved with local therapies such as external beam radiation therapy, photodynamic therapy, and transpupillary thermotherapy. The life expectancy of patients with choroidal metastases is generally poor but has been improving thanks to the therapeutic advances taking place.
U
veal metastasis is the most common intraocular malignancy and often the first sign of tumor dissemination. 1 An estimated 8-10% of patients with metastatic disease have ocular involvement.
2,3 Intraocular metastases almost always arise in the uvea, with retinal involvement being extremely rare. Uveal metastases usually involve the choroid (88% of cases) and infrequently the iris (9% of cases) or ciliary body (2% of cases). 4 The uveal tract's rich vascularity partly explains this predilection for metastases. 5 Further, the uveal microenvironment seems to predispose to metastases, as the uvea has the highest proportion of metastatic involvement in comparison to blood flow of any other tissue in the body. 6, 7 Breast and lung cancers are the most common primary malignancies that metastasize to the uvea. 4, 8 Retinal metastases are exceptionally rare. They can be difficult to diagnose as they mimic other conditions. 9
SymptomS and CliniCal FeatureS
The most common symptom of intraocular metastases is blurred vision or visual loss 1,4 due to macular or peripapillary retina involvement or due to exudative retinal detachment. 10 Infrequently, anteriorly located tumors may tilt the lens, causing visual loss. Rarely, they cause painful neovascular glaucoma or metastatic iritis.
11 Interestingly, about 12% of patients with metastasis from lung experience pain in the absence of glaucoma or uveitis, as compared with less than 5% of patients with metastasis from breast. 12, 13 Other symptoms include photopsia, metamorphopsia, and floaters. Diplopia and red eye have also been reported in cases of retinal metastases. 9 In a review of 109 eyes with choroidal metastases, symptoms at presentation included blurred or lost vision in 55.2% of cases, metamorphopsia in 11.5%, ocular pain in 11.5%, floaters in 11.5%, photopsia in 13.5%, and visual field defect in 15.6%. About 13% of patients were asymptomatic.
1
More than 90% of intraocular metastases are choroidal and most are postequatorial. It has been reported that up to 40% of choroidal metastases are located in the macular region 14 and differential blood flow of the macular area might be the reason for this predilection.
Choroidal metastases generally appear as a creamy white or pale yellow mass associated with subretinal fluid (Fig. 1A) . Infrequently, an orange color may indicate renal, thyroid, or carcinoid origin, whereas metastases from cutaneous melanoma can be pigmented or amelanotic. 4 Pigmented metastatic tumors have also been infrequently associated with breast carcinoma and lung carcinoma.
1 Metastatic optic disc involvement appears as a yellowwhite lesion, often associated with optic disc edema. Choroidal metastases may also show clusters of dark pigment resembling a "leopard skin" configuration and/or orange lipofuscin pigment on the tumor surface.
In 2 large studies, the mean number of metastases per eye reported was between 1.4 and 1.6. 1,4 Multiple tumors and bilateral metastases are more commonly associated with breast cancer; however, there are exceptions (Fig. 2) . 1 Typically, choroidal metastases appear flat or plateau shaped, often associated with serous retinal detachment. Very rarely, metastases may rupture the Bruch membrane and develop a mushroom shape. Rupture of the Bruch membrane has been associated with pulmonary origin of the primary tumor. Uveal metastasis may infrequently involve the ciliary body and iris.
15 Ciliary body metastases may be flat or dome shaped and are usually amelanotic. Iris metastases are usually white. Metastases originating from thyroid or kidney may be pink or orange, whereas those associated with cutaneous melanoma may be brown. Other features of iris metastases may include intrinsic and/or feeder vessels, secondary glaucoma, corectopia, pseudohypopyon, hyphema, and ocular hypertension. and unifocal.
18 However, they can appear as multiple tiny lesions, whereas some metastatic carcinomas can appear as a sizeable elevated mass. 9 Metastases from cutaneous melanoma tend to be pigmented.
19
Other clinical features of retinal metastasis include subretinal fluid, intraretinal edema, and vitreous and subretinal hemorrhage. 9, 18, 20 Vitreous cells are often associated with retinal metastases. 17 Cutaneous melanoma metastatic to vitreous presents as brown spheres of varying size. 21, 22 Vitreous cells overlying retinal metastases tend to be nonpigmented. The differential diagnosis of retinal metastases includes various inflammatory diseases such as toxoplasmosis chorioretinitis, cytomegalovirus retinitis, multifocal choroiditis, acute posterior multifocal placoid pigmentary epitheliopathy, and intraocular lymphoma. The presence of exudates and hemorrhages may mimic retinal microvascular diseases such as hypertensive retinopathy and diabetic retinopathy.
9 Vitreous floaters associated with intraocular metastases may mimic granulomatous uveitis, amyloidosis, asteroid hyalosis, or retinal lymphoma.
diagnostic ancillary tests

Color Photography
Photography allows documentation of tumor size and number. Some cameras, such as the Optos camera (Optos, Dunfermline, Scotland), may give a false impression of pigmentation.
Autofluorescence Imaging
Metastases usually show hyper-and hypofluorescent stippling in areas where the retinal pigment epithelium is disturbed (Fig. 1B) . 24 There may also be clumps of hyperfluorescent lipofuscin pigment, which can occur with other tumors such as melanoma and hemangioma.
Angiography
On fluorescein angiography, choroidal and retinal metastases are usually hypofluorescent in the early phases and hyperfluorescent in late phases. 18 Multiple foci of late pinpoint hyperfluorescence have also been reported. 25 The angiographic appearances reflect retinal pigment epithelial changes that are less conspicuous on ophthalmoscopy. 11 The so-called double circulation pattern, which is often seen in choroidal melanomas, is a rare finding in choroidal metastases. 26 Retinal metastasis may show prominent vascularity. 9 Indocyanine green angiography shows blockage of choroidal fluorescence and patchy surface staining.
Ultrasonography
Ultrasonography (Figs. 1C, E) is useful for measuring tumor dimensions, although lateral margins are frequently ill defined. Sequential measurement of tumor thickness is helpful in evaluating treatment response. The internal acoustic reflectivity of intraocular metastatic tumors is higher than that of most uveal melanomas but not as high as choroidal hemangiomas.
27 Rare mushroom-shaped metastases have an internal reflectivity that is equally high throughout the tumor unlike melanomas, which have a high reflectivity only in the prolapsed intraretinal "head" of the tumor. 28 Overlying retinal detachment is often seen. Choroidal detachment may be detected, albeit rarely.
29 Some metastases develop extraocular extension, which can be detected by ultrasonography. Retinal metastases show intermediate to high internal reflectivity and thickening of the retina.
9,30,31
Optical Coherence Tomography
Enhanced depth imaging optical coherence tomography (OCT) may be more sensitive than ultrasonography in the evaluation of small metastases.
32
Features of the metastasis on OCT may include anterior compression/obliteration of the overlying choriocapillaris, an irregular ("lumpy bumpy") anterior contour, and posterior shadowing (Fig. 1D ). Other OCT features include retinal pigment epithelial abnormalities 33 and subretinal fluid. 34 There may also be highly reflective speckles and outer retinal degeneration with photoreceptor layer changes. 32 Features of retinal metastases on OCT include thickened retina with hyperreflectance without any obvious changes in the underlying choroid.
35
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Magnetic Resonance Imaging and Computed Tomography
Magnetic resonance imaging (MRI) shows a well-demarcated choroidal mass that appears iso-intense on T1-weighted images and hypointense on T2-weighted images. 36 However, MRI findings can be varied. 37 Computed tomography (CT) shows poor definition and is rarely useful.
Ocular Tumor Biopsy
Intraocular biopsy is most useful in patients with a clinical suspicion of uveal metastasis but no evidence of primary malignancy despite systemic investigation. [38] [39] [40] In some centers, biopsy is performed in the first instance, subsequently targeting any imaging according to immunohistochemistry results.
1
Identification of the primary malignancy is important because this influences therapy. 41 Immunohistochemical evaluation may identify patients who could benefit from targeted therapy (eg, patients with HER2/neu-positive disease, who may benefit from adjuvant anti-HER2/neu directed therapy).
42 Furthermore, histopathological evaluation can identify estrogen receptor-and/or progesterone receptor-positive tumor cells, predicting response to endocrine therapy. 43 In cases of non-small cell lung cancer, DNA can be extracted from the biopsy material and assessed for the presence or absence of epidermal growth factor receptor (EGFR) mutations. Patients with EGFR-mutated bronchial carcinomas may have improved survival benefit with EGFR-tyrosine kinase inhibitors (gefitinib and erlotinib). 44, 45 In patients with a postequatorial metastasis, biopsy is usually performed transretinally through the pars plana with a fine needle or vitreous cutter.
1 Vitrectomy, retinopexy, and tamponade are not required. For anterior metastases, such as those involving the ciliary body, a transscleral approach may be preferable. 40 Ideally, the pathologist or cytologist should be present in the operating room for the biopsy to ensure that an adequate specimen has been obtained for analysis.
Systemic Assessment
Most patients with choroidal metastases have a history of malignancy.
1,4 However, the possibility of dual pathology should be considered because patients with systemic malignancy can also develop uveal melanoma and other primary intraocular tumors.
In patients with a known history of a primary malignancy, the systemic work-up depends on the location and status of the primary tumor and the history of the disease. Such investigation is usually performed by a medical oncologist and includes imaging of the brain, chest, abdomen, and pelvis in addition to other tests indicated by clinical findings.
11
In patients with no history of systemic malignancy, systemic investigations are performed, which include serum studies for relevant cancer markers and mammography along with CT, MRI, and/ or positron emission tomography scans of the chest, abdomen, and pelvis. 46 In a significant percentage of cases, no detectable primary tumor can be found.
1,4 Biopsy of the choroidal lesion may be very helpful in identifying the primary site of disease in these cases.
1
It is important to detect any brain metastases that are present so that any radiotherapy to such lesions can be administered at the same time as ocular irradiation. It is also important to detect bone metastases early so as to prevent fractures that might complicate treatment.
management
Management of patients with choroidal metastases depends on their systemic status along with the number, location, and laterality of the ocular tumors. Treatment options include systemic chemotherapy, immunotherapy, hormone therapy, whole eye radiotherapy, plaque radiotherapy, transpupillary radiotherapy, and photodynamic therapy (PDT). Observation may be considered for small peripheral metastatic lesions in patients who have a poor systemic status. Enucleation may be necessary for blind painful eyes.
Systemic treatment
If the patient is about to start systemic therapy, it may be reasonable to delay ocular treatment until the effect of systemic treatment can be assessed. This is because ocular metastases can regress dramatically, or even completely, with such therapy.
47-50
Many choroidal metastases from breast carcinomas express estrogen or progesterone receptors, making therapy with tamoxifen and aromatase inhibitors effective. 51, 52 Close surveillance is necessary, however, because the metastases may recur, causing irreversible visual loss if local treatment is not administered promptly.
Surveillance is also necessary to detect and treat any adverse effects caused by systemic therapy. These include blepharitis, conjunctivitis, punctal stenosis after cytotoxic chemotherapy, crystalline maculopathy and optic neuropathy after tamoxifen, and serous retinal detachments after MEK inhibitors. The spectrum of adverse effects is expanding as the variety of new drugs increases.
ocular treatment
Radiation Therapy
Radiation treatment modalities include external beam radiation therapy (EBRT), proton beam radiotherapy (PBT), brachytherapy, and stereotactic radiotherapy. 1, 53 Metastases from the lung are less radiosensitive than those from the breast, and some tumors, such as leiomyosarcoma, are highly radio-resistant.
Radiation-induced morbidity includes cataract, iris neovascularization, neovascular glaucoma, radiation retinopathy, and optic neuropathy. 54 In addition, teletherapy (ie, photon therapy, stereotactic radiotherapy, and PBT) can cause skin erythema, madarosis, conjunctivitis, and keratopathy. 55 Complications depend on the type of radiotherapy, radiation dose, degree of fractionation, concurrent chemotherapy, and comorbidities such as diabetes. However, many patients with choroidal metastases do not survive long enough to develop radiation-induced complications. A study of 578 eyes with metastasis reported retinopathy and optic neuropathy in only 2% of patients after external beam irradiation.
56
External Beam Radiation Therapy
External beam radiation therapy is the most widely applied local treatment modality against ocular metastatic disease.
53 It induces tumor regression in up to 94% of patients. 1, 52, 57, 58 Fragmentation of radiation treatment is widely practiced as a means of avoiding radiation-induced complications (eg, 30-40 Gy in 10-20 fractions of 2-3 Gy over 2 to 4 weeks).
However, an extended treatment protocol may be highly inconvenient in critically ill patients, so less fractionated therapy may be proposed (eg, 25 Gy delivered in 5 fractions).
Brachytherapy
Brachytherapy provides more focused, targeted radiotherapy than EBRT. 1, 52, 59 Radioactive plaques using radioisotopes such as iodine-125, ruthenium-106, or palladium-103 may be used, delivering an apex dose of approximately 45-70 Gy over 3-4 days. Shields et al 59 reported 94% of lasting regression in 36 patients treated with choroidal metastases.
The main advantage of brachytherapy is the short treatment time as compared with EBRT, although a plaque may only be used for patients with a solitary choroidal metastasis of appropriate size, depth, and location. A significant disadvantage of brachytherapy is the need for hospitalization and the requirement of 2 surgical procedures for placement and removal of the plaque.
59,60
Proton Beam Radiotherapy
Proton beam radiotherapy provides highly localized radiation with minimal fractionation. In a retrospective study of 63 patients treated with PBT (2 fractions of 14 cobalt gray equivalents) for choroidal metastases, tumor regression was documented in 84% of patients and stable disease was reported in 14%.
55 Tantalum markers are not required for tumor localization and so surgery is avoided.
Stereotactic Radiosurgery
Stereotactic radiosurgery (SRS) utilizes multiple precisely focused radiation beams delivering high doses in a limited number of fractions. This technique administers ablative doses of radiation to a small volume, thereby maximizing local control while sparing critical adjacent normal tissues.
11 Stereotactic radiotherapy can offer good results, in particular when plaque radiotherapy is precluded by large tumor size or proximity to the optic disc. There are different technologies that may be used to deliver SRS, including the linear accelerator and Leksell gamma knife (GK). With a linear accelerator, multiple gamma rays are focused on the lesion, delivering 30 Gy over 10 days.
52 Regression of choroidal metastasis from breast carcinoma has been reported after 1 treatment with Leksell GK SRS delivering 18 Gy.
61
Photodynamic Therapy
Photodynamic therapy has recently been used for the treatment of small choroidal metastases with promising results. 62, 63 Complete tumor regression has been reported in 81% of cases.
63
Photodynamic therapy achieves tumor destruction by producing highly reactive oxygen singlet, by activating immune response against tumor cells, and by producing intravascular thrombosis and subsequent tumor infarction. 62 More extensive trials are warranted, however, to determine more precisely the effectiveness of PDT in the treatment of choroidal metastases.
Transpupillary Thermotherapy
Transpupillary thermotherapy (TTT) is a technique in which heat is delivered to the choroid and retinal pigment epithelium using an 810 nm diode laser. The heating effect may induce vascular thrombosis, thermal inhibition of angiogenesis, induction of fibrosis, and tumor necrosis. 64 Regression of small metastases after TTT alone has been reported. 65, 66 Some authors have combined TTT with brachytherapy or EBRT. 67, 68 Complications of TTT may include retinal burns, with loss of central vision after treatment of juxtafoveal tumors.
Intravitreal Anti-Angiogenic Agents
Small case series have recently demonstrated regression of intraocular metastases after intravitreal administration of bevacizumab, 69-73 a selective vascular endothelial growth factor (VEGF)-A inhibitor, which is approved for the treatment of several cancers as an intravenous chemotherapeutic agent. However, this treatment is ineffective in some patients. 74, 75 Some authors have therefore advocated systemic bevacizumab administered in combination with chemotherapy.
76 Intravitreal anti-VEGF therapy may be helpful in the treatment of associated choroidal exudative detachment and radiation-induced retinopathy. 54 Although intravitreal anti-VEGF may be helpful as an adjuvant treatment in selected cases, its role as the primary treatment of choroidal metastases has yet to be defined. Close surveillance is necessary so as not to miss any opportunities for conserving vision if the treatment fails.
75
Surgical Resection
Local resection may rarely be indicated. One of the authors (B.D.) has successfully performed a transscleral local resection of a large choroidal metastasis from primary pulmonary leiomyosarcoma that did not respond to radiotherapy. 77 Vitrectomy may be helpful in improving vision in patients with vitreous metastases.
78
Vitrectomy and retinectomy have been reported in cases of retinal metastasis. 20, 79, 80 Enucleation may be required in cases of an irreversibly blind and painful eye associated in most cases with persistent tumor growth and neovascular glaucoma. Most of these cases have metastasis from lung carcinoma.
prognoSiS
Life expectancy is generally poor in patients with intraocular metastases.
11 A recent case series of 96 patients indicated that in deceased patients, the median survival time between diagnosis of choroidal metastasis and death was only 6 months (range, 0.5 to 47).
1 Survival time is lower in patients with lung cancer than in those with breast cancer. Life expectancy is short when nonocular metastases are also present.
Retinal and vitreous metastases are associated with a particularly poor prognosis.
Response of choroidal metastases to local therapy is usually good. We have reported tumor regression in about 94% of patients, with conservation of vision in about 75% of cases.
1 However, recurrences occur in about 12% of cases.
After treatment of unilateral disease, metastasis in the fellow eye is seen in approximately 15-20% of patients.
ConCluSionS
Advances in ocular imaging and biopsy have enhanced diagnostic accuracy. Ocular outcomes have improved thanks to the development of more effective systemic therapy and advances in ocular treatment. The decision to treat ocular metastasis should be made in consultation with the oncologist and radiation oncologist. The general status of the patient should be considered as well. 
